AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
|Articles|October 27, 2014
Is Pfizer Ready for Another Acquisition?
After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover?
Advertisement
After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This
Advertisement
Related to this article
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
FDA is launching the Rare Disease Framework Initiative, aiming to tailor drug development and review requirements to the realities of small patient populations.
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
Gilead and Vir Biotechnology Enter a $1.87 billion collaboration to discover three PRO-XTEN dual-masked T-cell engagers aimed at solid tumors.
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5